Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
TRANSMET Regimen Proves Safe, Feasible for Definitively Unresectable CRC Liver Metastasis
Switch Ramucirumab/Paclitaxel Maintenance Yields Favorable Outcomes in HER2– Gastric Cancer
TAS-102 Followed By Regorafenib Identified As Optimal Treatment Sequence in Pretreated mCRC
2 Commerce Drive
Cranbury, NJ 08512